Diverse and rich fortified cultural heritage of the Iberian Peninsula. Basis for culture tourism with the European Culture Route Fortified Monuments FORTE CULTURA®

[EN] Fortresses are architectural pearls, cultural sites, event locations, experience places and memorials, mostly situated at breath-taking places on mountains, rivers or in the under-ground. Fortresses are monuments of common European history, they mirror the past into the present, connect cultures and offer deep insights into the historical conflicts. Fortified monuments are part of what makes Europe unique and attractive. This cultural heritage has to be preserved and made accessible for the culture tourism at the same time. The Iberian fortified heritage has big potential for new culture touristic topics and travel routes away from mass tourism. Therefore, cultural routes are a useful instrument. The European Culture Route Fortified Monuments –FORTE CULTURA®– is the European umbrella brand for fortress tourism. It offers useful instruments for international marketing of fortified monuments. The implementation of the attractive architectura militaris of the Iberian Peninsula into the culture route FORTE CULTURA® makes it possible to network this culture asset touristically, make it visible and experienceable on international tourism markets and market it Europe-wide. By implementing a new touristic regional brand “FORTE CULTURA – Iberian Fortified Heritage” the qualified culture tourism will be addressed. This supports a balance between over and under presented monuments and extends the sphere of activity of local actors onto whole Europe.Neumann, H.; Röder, D.; Röder, H. (2020). Diverse and rich fortified cultural heritage of the Iberian Peninsula. Basis for culture tourism with the European Culture Route Fortified Monuments FORTE CULTURA®. Editorial Universitat Politècnica de València. 971-976. https://doi.org/10.4995/FORTMED2020.2020.11394OCS97197

Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Production costs have been covered by ESMO from central funds

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

The third edition of Flow Cytometry Guidelines provides the key aspects to consider when performing flow cytometry experiments and includes comprehensive sections describing phenotypes and functional assays of all major human and murine immune cell subsets. Notably, the Guidelines contain helpful tables highlighting phenotypes and key differences between human and murine cells. Another useful feature of this edition is the flow cytometry analysis of clinical samples with examples of flow cytometry applications in the context of autoimmune diseases, cancers as well as acute and chronic infectious diseases. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid. All sections are written and peer‐reviewed by leading flow cytometry experts and immunologists, making this edition an essential and state‐of‐the‐art handbook for basic and clinical researchers.DFG, 389687267, Kompartimentalisierung, Aufrechterhaltung und Reaktivierung humaner Gedächtnis-T-Lymphozyten aus Knochenmark und peripherem BlutDFG, 80750187, SFB 841: Leberentzündungen: Infektion, Immunregulation und KonsequenzenEC/H2020/800924/EU/International Cancer Research Fellowships - 2/iCARE-2DFG, 252623821, Die Rolle von follikulären T-Helferzellen in T-Helferzell-Differenzierung, Funktion und PlastizitätDFG, 390873048, EXC 2151: ImmunoSensation2 - the immune sensory syste

Solar-blind pyrometric temperature measurement under concentrated solar irradiation

The surface temperature distribution of high temperature solar materials is a key parameter in concentrating solar thermal applications. As contact thermometry is often not appropriate in the presence of high-flux solar irradiation, pyrometric techniques can be adopted. However, depending on the optical properties of the sample, special measurement treatments are required to eliminate the bias in the pyrometric measurement resulting from the single and multiple surface reflections of incoming solar radiation. Several pyrometric methodologies for particular applications have been reported in literature. In this paper a more general approach to this technique and its adaptation for the use in high temperature solar receivers is presented. The measurement requirements including the necessity and type of a selective filter are obtained from the analysis of the spectral bi-directional reflectance and the operational range of temperature. According to these conditions a classification of materials encountered in solar receivers is given and adequate measurement methodologies are suggested for each type of receiver and temperature range

Shock hydrodynamics and blast waves /

Work performed at the Los Alamos Scientific Laboratory."Date Declassified: April 22, 1949.""October 28, 1944.""This report is based on LADC-549."Includes bibliographic references (p. 60).Reproduced from typewritten copy.Mode of access: Internet